Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Expression of PAFR as Part of a Prosurvival Response to Chemotherapy: A Novel Target for Combination Therapy in Melanoma

Texto completo
Autor(es):
Onuchic, Ana Claudia [1] ; Machado, Camila M. L. [1] ; Saito, Renata F. [1] ; Rios, Francisco J. [2] ; Jancar, Sonia [2] ; Chammas, Roger [1]
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Dept Radiol & Oncol, Inst Canc Estado Sao Paulo, Fac Med, BR-01246903 Sao Paulo - Brazil
[2] Univ Sao Paulo, Dept Imunol, Inst Ciencias Biomed, BR-05508900 Sao Paulo - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: Mediators of Inflammation; 2012.
Citações Web of Science: 26
Resumo

Melanoma cells express the platelet-activating factor receptor (PAFR) and, thus, respond to PAF, a bioactive lipid produced by both tumour cells and those in the tumour microenvironment such as macrophages. Here, we show that treatment of a human melanoma SKmel37 cell line with cisplatin led to increased expression of PAFR and its accumulation. In the presence of exogenous PAF, melanoma cells were significantly more resistant to cisplatin-induced cell death. Inhibition of PAFR-dependent signalling pathways by a PAFR antagonist (WEB2086) showed chemosensitisation of melanoma cells in vitro. Nude mice were inoculated with SKmel37 cells and treated with cisplatin and WEB2086. Animals treated with both agents showed significantly decreased tumour growth compared to the control group and groups treated with only one agent. PAFR accumulation and signalling are part of a prosurvival program of melanoma cells, therefore constituting a promising target for combination therapy for melanomas. (AU)

Processo FAPESP: 08/00247-8 - Avaliação citométrica do microambiente do melanoma murino na vigência de quimioterapia experimental: análise do infiltrado inflamatório e da cinética de repopulação tumoral.
Beneficiário:Ana Cláudia Onuchic
Linha de fomento: Bolsas no Brasil - Iniciação Científica
Processo FAPESP: 98/14247-6 - Center for Research on Cell-Based Therapy
Beneficiário:Marco Antonio Zago
Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs